WILMINGTON, Mass., Feb. 16 /PRNewswire/ -- OmniSonics Medical Technologies, Inc. today announced that it has transitioned to a full U.S. market release of the Resolution(R) Endovascular System. The full market release follows the completion of a limited release that commenced upon FDA clearance in December 2005 for use in the treatment of thrombosed, synthetic dialysis access grafts. OmniSonics has initiated the expansion of the treatment of patients at additional healthcare facilities and will continue to roll out the Resolution Endovascular System as the Company's sales and operations infrastructures expand.
In occlusions that varied in age from several weeks to three months, the Resolution Endovascular System consistently re-established flow and resolved the clot in less than six minutes of application time.
In addition to clearing aged-mature thrombus, physicians reported successful clot resolution and flow restoration in procedures where the patient was referred for treatment after having previously failed treatment utilizing another percutaneous thrombectomy technique. "The Resolution Therapeutic Wire has become our secret weapon," stated Dr. Carlo Dall'Olmo (Michigan Vascular Center, Flint, MI) after clearing a graft that had failed treatment using another mechanical approach.
About the Resolution Endovascular System
The Resolution Endovascular System consists of two primary components: a Generator and a Resolution System Kit. The Resolution System Kit consists of a handpiece with an attached wire and accessory irrigation tubing. The Generator controls an electrical signal to power the handpiece. The handpiece converts the electronic signal to low-power ultrasonic energy transmitted down the length of the Resolution Therapeutic Wire. The Resolution Therapeutic Wire distributes ultrasonic energy waves that generate a cavitational streaming effect that breaks the fibrin bonds.
The Resolution Endovascular System is easy to set up: Power-on, Plug-in, Prime. Treatment with the Resolution Endovascular System utilizes typical interventional technique and is compatible with common interventional devices (5Fr and .035" wire compatibility).
About OmniSonics Medical Technologies, Inc.
OmniSonics Medical Technologies, Inc., headquartered in Wilmington, Massachusetts, is a privately-held medical device company focused on bringing breakthrough products for vascular occlusive disease to market. The Company's patented OmniWave(TM) Technology is the first technology that enables the delivery of acoustic energy over the entire active length of a small diameter wire. OmniWave is designed to have broad applications in peripheral and coronary vascular occlusive conditions, which afflict millions of people worldwide.
OmniSonics has recently been honored by Frost & Sullivan as the "Mechanical Thrombectomy Technology Innovation of the Year" for 2005 for the Company's unique OmniWave Technology platform.
For more information, please visit the Company's website at http://www.omnisonics.com.
Contact: Media: Daniel E. Geffken OmniSonics Medical Technologies, Inc. Senior Vice President, Business Development and Chief Financial Officer (978) 657-9980 x320 dgeffken@omnisonics.com David Nangle OmniSonics Medical Technologies, Inc. Marketing Support Specialist (978) 657-9980 x503 dnangle@omnisonics.com
OmniSonics Medical Technologies, Inc.CONTACT: Daniel E. Geffken, Senior Vice President, Business Developmentand Chief Financial Officer of OmniSonics Medical Technologies, Inc.,+1-978-657-9980 ext. 320, dgeffken@omnisonics.com; or David Nangle,Marketing Support Specialist of OmniSonics Medical Technologies, Inc.,+1-978-657-9980 ext. 503, dnangle@omnisonics.com
Web site: http://www.omnisonics.com//
